Skip to main content
SpringerLink
Log in

Medical Therapy of HCC

  • Chapter
  • First Online:
Hepatocellular Carcinoma

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

Systemic chemotherapies have been evaluated for many years, with minimal responses and little survival advantage. Regional chemotherapy produces high response rates and two randomized trials also showed survival advantage, using cisplatin or doxorubicin, each plus embolization. 90Yttrium also looks promising now. The combination of TACE or 90Yttrium with the anti-angiogenics and cell cycle inhibitors is beginning to be explored.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bartlett D, Marsh W, Carr BI. Hepatocellular carcinoma. In: DeVita et al., ed. Principles and Practice of Oncology. 7th ed: Lippincott; 2004.

    Google Scholar 

  2. Dodd GD, 3rd, Carr BI. Percutaneous biopsy of portal vein thrombus: a new staging technique for hepatocellular carcinoma. AJR Am J Roentgenol 1993;161:229–33.

    PubMed  Google Scholar 

  3. Dusenbery D, Dodd GD, 3rd, Carr BI. Percutaneous fine-needle aspiration of portal vein thrombi as a staging technique for hepatocellular carcinoma. Cytologic findings of 46 patients. Cancer 1995;75:2057–62.

    PubMed  CAS  Google Scholar 

  4. Haddow A. Cellular inhibition and origin of cancer. Acta Unio Int Contra Cancrum 1938;3:342–52

    Google Scholar 

  5. MacNider W. A study of the acquired resistance of fixed tissue cells morphologically altered through process of repair. II. The resistance of liver epithelium altered morphologically as a result of an injury from uranium, followed by repair to the hepatotoxic action of chloroform. J Pharm Exp Ther 1936;56:373–82.

    CAS  Google Scholar 

  6. Solt D, Farber E. New principle for the analysis of chemical carcinogenesis Nature 1976;263:701–3.

    CAS  Google Scholar 

  7. Carr BI, Laishes BA. Carcinogen-induced drug resistance in rat hepatocytes. Cancer Res 1981;41:1715–9.

    PubMed  CAS  Google Scholar 

  8. Sciarrino E, Simonetti RG, Le Moli S, Pagliaro L. Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer 1985;56:2751–5.

    PubMed  CAS  Google Scholar 

  9. Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, Block JB, Tong M, Chan KK. Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep 1984;68:487–91.

    PubMed  CAS  Google Scholar 

  10. Ihde DC, Kane RC, Cohen MH, McIntire KR, Minna JD. Adriamycin therapy in American patients with hepatocellular carcinoma. Cancer Treat Rep 1977;61:1385–7.

    PubMed  CAS  Google Scholar 

  11. Falkson G, MacIntyre JM, Moertel CG, Johnson LA, Scherman RC. Primary liver cancer. An Eastern Cooperative Oncology Group Trial. Cancer 1984;54:970–7.

    PubMed  CAS  Google Scholar 

  12. Falkson G, MacIntyre JM, Schutt AJ, et al. Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma. J Clin Oncol 1984;2:581–4.

    PubMed  CAS  Google Scholar 

  13. Ravry MJ, Omura GA, Bartolucci AA. Phase II evaluation of doxorubicin plus bleomycin in hepatocellular carcinoma: a Southeastern Cancer Study Group trial. Cancer Treat Rep 1984;68:1517–8.

    PubMed  CAS  Google Scholar 

  14. Cavalli F, Rozencweig M, Renard J, Goldhirsch A, Hansen HH. Phase II study of oral VP-16-213 in hepatocellular carcinoma. Eur J Cancer Clin Oncol 1981;17:1079–82.

    PubMed  CAS  Google Scholar 

  15. Melia WM, Johnson PJ, Williams R. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Cancer 1983;51:206–10.

    PubMed  CAS  Google Scholar 

  16. Melia WM, Westaby D, Williams R. Diamminodichloride platinum (cis-platinum) in the treatment of hepatocellular carcinoma. Clin Oncol 1981;7:275–80.

    PubMed  CAS  Google Scholar 

  17. Ravry MJ, Omura GA, Bartolucci AA, Einhorn L, Kramer B, Davila E. Phase II evaluation of cisplatin in advanced hepatocellular carcinoma and cholangiocarcinoma: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986;70:311–2.

    PubMed  CAS  Google Scholar 

  18. Falkson G, Ryan LM, Johnson LA, et al. A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer 1987;60:2141–5.

    PubMed  CAS  Google Scholar 

  19. Colleoni M, Buzzoni R, Bajetta E, et al. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer 1993;72:3196–201.

    PubMed  CAS  Google Scholar 

  20. Chao Y, Chan WK, Birkhofer MJ, et al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 1998;78:34–9.

    PubMed  CAS  Google Scholar 

  21. Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003;21:421–7.

    PubMed  CAS  Google Scholar 

  22. Patt YZ, Hoque A, Roh M, et al. Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication. Am J Clin Oncol 1999;22:209–13.

    PubMed  CAS  Google Scholar 

  23. Bobbio-Pallavicini E, Porta C, Moroni M, et al. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study. Eur J Cancer 1997;33:1784–8.

    PubMed  CAS  Google Scholar 

  24. Okada S, Okusaka T, Ueno H, et al. Phase II trial of cisplatin, mitroxantrone and continuous infusion 5-fluorouracil for hepatocellular carcinoma. Proc ASCO 1999;18:248A.

    Google Scholar 

  25. Guan Z, Wang Y, Maoleekoonpairoj S, et al. Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer 2003;89:1865–9.

    PubMed  CAS  Google Scholar 

  26. Taieb J, Bonyhay L, Golli L, et al. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 2003;98:2664–70.

    PubMed  CAS  Google Scholar 

  27. Lee J, Park JO, Kim WS, et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 2004;54:385–90.

    PubMed  CAS  Google Scholar 

  28. Ikeda M, Okusaka T, Ueno H, Takezako Y, Morizane C. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer 2005;103:756–62.

    PubMed  CAS  Google Scholar 

  29. Zhu AX, Fuchs CS, Clark JW, et al. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist 2005;10:392–8.

    PubMed  CAS  Google Scholar 

  30. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:1898–903.

    PubMed  CAS  Google Scholar 

  31. Kim SJ, Seo HY, Choi JG, et al. Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2006;57:436–42.

    PubMed  CAS  Google Scholar 

  32. Park SH, Lee Y, Han SH, et al. Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer 2006;6:3.

    PubMed  Google Scholar 

  33. Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007;109:1384–90.

    PubMed  CAS  Google Scholar 

  34. Li S, Niu Z, Tian H, et al. Treatment of advanced hepatocellular carcinoma with gemcitabine plus oxaliplatin. Hepatogastroenterology 2007;54:218–23.

    PubMed  CAS  Google Scholar 

  35. Uhm JE, Park JO, Lee J, et al. A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma. Cancer Chemother Pharmacol 2008;23:23.

    Google Scholar 

  36. Asnacios A, Fartoux L, Romano O, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008;112:2733–9.

    PubMed  CAS  Google Scholar 

  37. Koda M, Murawaki Y, Mitsuda A, et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer 2001;92:1516–24.

    PubMed  CAS  Google Scholar 

  38. Leung TW, Johnson PJ. Systemic therapy for hepatocellular carcinoma. Semin Oncol 2001;28:514–20.

    PubMed  CAS  Google Scholar 

  39. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429–42.

    PubMed  CAS  Google Scholar 

  40. Martin RC, 2nd, Jarnagin WR. Randomized clinical trials in hepatocellular carcinoma and biliary cancer. Surg Oncol Clin N Am 2002;11:193–205, x.

    PubMed  Google Scholar 

  41. Mathurin P, Rixe O, Carbonell N, et al. Review article: Overview of medical treatments in unresectable hepatocellular carcinoma—an impossible meta-analysis? Aliment Pharmacol Ther 1998;12:111–26.

    Google Scholar 

  42. Schwartz JD, Beutler AS. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. Anticancer Drugs 2004;15:439–52.

    PubMed  CAS  Google Scholar 

  43. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997;8:117–36.

    PubMed  CAS  Google Scholar 

  44. Thomas MB, O'Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol 2008;15:1008–14.

    PubMed  Google Scholar 

  45. Sasaki Y, Imaoka S, Kasugai H, et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 1987;60:1194–203.

    PubMed  CAS  Google Scholar 

  46. Kasugai H, Kojima J, Tatsuta M, et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology 1989;97:965–71.

    PubMed  CAS  Google Scholar 

  47. Ohnishi K, Tsuchiya S, Nakayama T, et al. Arterial chemoembolization of hepatocellular carcinoma with mitomycin C microcapsules. Radiology 1984;152:51–5.

    PubMed  CAS  Google Scholar 

  48. Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma—a randomized controlled trial. Gastroenterology 1988;94:453–6.

    PubMed  CAS  Google Scholar 

  49. Fujimoto S, Miyazaki M, Endoh F, Takahashi O, Okui K, Morimoto Y. Biodegradable mitomycin C microspheres given intra-arterially for inoperable hepatic cancer. With particular reference to a comparison with continuous infusion of mitomycin C and 5-fluorouracil. Cancer 1985;56:2404–10.

    PubMed  CAS  Google Scholar 

  50. Audisio RA, Doci R, Mazzaferro V, et al. Hepatic arterial embolization with microencapsulated mitomycin C for unresectable hepatocellular carcinoma in cirrhosis. Cancer 1990;66:228–36.

    PubMed  CAS  Google Scholar 

  51. Kobayashi H, Hidaka H, Kajiya Y, et al. Treatment of hepatocellular carcinoma by transarterial injection of anticancer agents in iodized oil suspension or of radioactive iodized oil solution. Acta Radiol Diagn (Stockh) 1986;27:139–47.

    CAS  Google Scholar 

  52. Kanematsu T, Furuta T, Takenaka K, et al. A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology 1989;10:98–102.

    PubMed  CAS  Google Scholar 

  53. Shibata J, Fujiyama S, Sato T, Kishimoto S, Fukushima S, Nakano M. Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer 1989;64:1586–94.

    PubMed  CAS  Google Scholar 

  54. Konno T, Maeda H, Iwai K, et al. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol 1983;19:1053–65.

    Google Scholar 

  55. Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990;11:181–4.

    PubMed  CAS  Google Scholar 

  56. Carr B, Starzl T, Iwatsuki S, et al. Aggressive treatment for advanced hepatocellular carcinoma (HCC): High response rates and prolonged survival. Hepatology 1991;14:243.

    Google Scholar 

  57. Venook AP, Stagg RJ, Lewis BJ, et al. Chemoembolization for hepatocellular carcinoma. J Clin Oncol 1990;8:1108–14.

    PubMed  CAS  Google Scholar 

  58. Ohnishi K, Sugita S, Nomura F, Iida S, Tanabe Y. Arterial chemoembolization with mitomycin C microcapsules followed by transcatheter hepatic artery embolization for hepatocellular carcinoma. Am J Gastroenterol 1987;82:876–9.

    PubMed  CAS  Google Scholar 

  59. Beppu T, Ohara C, Yamaguchi Y, et al. A new approach to chemoembolization for unresectable hepatocellular carcinoma using aclarubicin microspheres in combination with cisplatin suspended in iodized oil. Cancer 1991;68:2555–60.

    PubMed  CAS  Google Scholar 

  60. Trinchet JC, et al. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 1995;332:1256–61.

    Google Scholar 

  61. Chang JM, Tzeng WS, Pan HB, Yang CF, Lai KH. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer 1994;74:2449–53.

    PubMed  CAS  Google Scholar 

  62. Stuart K, Stokes K, Jenkins R, Trey C, Clouse M. Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization. Cancer 1993;72:3202–9.

    PubMed  CAS  Google Scholar 

  63. Bruix J, Castells A, Montanya X, et al. Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology 1994;20:643–50.

    PubMed  CAS  Google Scholar 

  64. Carr BI, Zajko A, Bron K, Orons P, Sammon J, Baron R. Phase II study of Spherex (degradable starch microspheres) injected into the hepatic artery in conjunction with doxorubicin and cisplatin in the treatment of advanced-stage hepatocellular carcinoma: interim analysis. Semin Oncol 1997;24:S6-97-S6-9.

    Google Scholar 

  65. Carr BI, Zajko A, Bron K, et al. Prospective randomized study of intrahepatic artery chemotherapy with cisplatin and doxorubin, with or without Lipiodol in the treatment of advanced-stage hepatocellular carcinoma. Proc Am Soc Clin Oncol 1993;12:668.

    Google Scholar 

  66. Carr BI. Hepatic artery chemoembolization for advanced stage HCC: experience of 650 patients. Hepatogastroenterology 2002;49:79–86.

    PubMed  CAS  Google Scholar 

  67. Ngan H, Lai CL, Fan ST, Lai EC, Yuen WK, Tso WK. Treatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of cisplatin in iodized oil and gelfoam. Clin Radiol 1993;47:315–20.

    PubMed  CAS  Google Scholar 

  68. Yamamoto M, Iizuka H, Fujii H, Matsuda M, Miura K. Hepatic arterial infusion of interleukin-2 in advanced hepatocellular carcinoma. Acta Oncol 1993;32:43–51.

    PubMed  CAS  Google Scholar 

  69. Kawai S, Tani M, Okamura J, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma—a comparison between L-TAE with farmorubicin and L-TAE with adriamycin: preliminary results (second cooperative study). Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 1994;33 Suppl:S97–102.

    PubMed  Google Scholar 

  70. Yoshimi F, Nagao T, Inoue S, et al. Comparison of hepatectomy and transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: necessity for prospective randomized trial. Hepatology 1992;16:702–6.

    PubMed  CAS  Google Scholar 

  71. Epstein B, Ettinger D, Leichner PK, Order SE. Multimodality cisplatin treatment in nonresectable alpha-fetoprotein-positive hepatoma. Cancer 1991;67:896–900.

    PubMed  CAS  Google Scholar 

  72. Rougier P, Roche A, Pelletier G, Ducreux M, Pignon JP, Etienne JP. Efficacy of chemoembolization for hepatocellular carcinomas: experience from the Gustave Roussy Institute and the Bicetre Hospital. J Surg Oncol Suppl 1993;3:94–6.

    PubMed  CAS  Google Scholar 

  73. Onohara S, Kobayashi H, Itoh Y, Shinohara S. Intra-arterial cis-platinum infusion with sodium thiosulfate protection and angiotensin II induced hypertension for treatment of hepatocellular carcinoma. Acta Radiol 1988;29:197–202.

    PubMed  CAS  Google Scholar 

  74. Kajanti M, Rissanen P, Virkkunen P, Franssila K, Mantyla M. Regional intra-arterial infusion of cisplatin in primary hepatocellular carcinoma. A phase II study. Cancer 1986;58:2386–8.

    PubMed  CAS  Google Scholar 

  75. Nagasue N, Yukaya H, Okamura J, et al. [Intra-arterial administration of epirubicin in the treatment of non-resectable hepatocellular carcinoma. Epirubicin Study Group for Hepatocellular Carcinoma]. Gan To Kagaku Ryoho 1986;13:2786–92.

    PubMed  CAS  Google Scholar 

  76. Carr B. Escalating cisplatin doses by intrahepatic infusion for advanced stage hepatocellular carcinoma. Proc ASCO 1996;15:23.

    Google Scholar 

  77. Lin CP, Yu HC, Cheng JS, et al. Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5-flourouracil for unresectable advanced hepatocellular carcinoma. J Chin Med Assoc 2004;67:602–10.

    PubMed  Google Scholar 

  78. Jang BK, Kwon KM, Chung WJ, et al. [Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil and cisplatin]. Korean J Hepatol 2004;10:271–8.

    PubMed  Google Scholar 

  79. Kawai S, Okamura J, Ogawa M, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma—a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 1992;31 Suppl:S1–6.

    PubMed  Google Scholar 

  80. Kawai S, Tani M, Okamura J, et al. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Semin Oncol 1997;24:S6-38–S6-45.

    Google Scholar 

  81. Watanabe S, Nishioka M, Ohta Y, Ogawa N, Ito S, Yamamoto Y. Prospective and randomized controlled study of chemoembolization therapy in patients with advanced hepatocellular carcinoma. Cooperative Study Group for Liver Cancer Treatment in Shikoku area. Cancer Chemother Pharmacol 1994;33 Suppl:S93–6.

    PubMed  Google Scholar 

  82. Hatanaka Y, Yamashita Y, Takahashi M, et al. Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management. Radiology 1995;195:747–52.

    PubMed  CAS  Google Scholar 

  83. Uchino J, Une Y, Sato Y, Gondo H, Nakajima Y, Sato N. Chemohormonal therapy of unresectable hepatocellular carcinoma. Am J Clin Oncol 1993;16:206–9.

    PubMed  CAS  Google Scholar 

  84. Madden MV, Krige JE, Bailey S, et al. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993;34:1598–600.

    PubMed  CAS  Google Scholar 

  85. Chung YH, Song IH, Song BC, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000;88:1986–91.

    PubMed  CAS  Google Scholar 

  86. Yoshikawa M, Saisho H, Ebara M, et al. A randomized trial of intrahepatic arterial infusion of 4'-epidoxorubicin with Lipiodol versus 4'-epidoxorubicin alone in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 1994;33 Suppl:S149–52.

    PubMed  Google Scholar 

  87. Kajanti M, Pyrhonen S, Mantyla M, Rissanen P. Intra-arterial and intravenous use of 4' epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison. Am J Clin Oncol 1992;15:37–40.

    PubMed  CAS  Google Scholar 

  88. Tzoracoleftherakis EE, Spiliotis JD, Kyriakopoulou T, Kakkos SK. Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma. Hepatogastroenterology 1999;46:1122–5.

    PubMed  CAS  Google Scholar 

  89. Bhattacharya S, Novell JR, Dusheiko GM, Hilson AJ, Dick R, Hobbs KE. Epirubicin-Lipiodol chemotherapy versus 131iodine-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer 1995;76:2202–10.

    PubMed  CAS  Google Scholar 

  90. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998;27:1578–83.

    PubMed  CAS  Google Scholar 

  91. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998;29:129–34.

    PubMed  CAS  Google Scholar 

  92. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164–71.

    PubMed  CAS  Google Scholar 

  93. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734–9.

    PubMed  Google Scholar 

  94. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224:47–54.

    PubMed  Google Scholar 

  95. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30:6–25.

    PubMed  Google Scholar 

  96. Carr BI, Dvorchik I. Effects of cisplatin dose intensity on response and survival for patients with unresectable and untransplantable hepatocellular carcinoma: an analysis of 57 patients. Gan To Kagaku Ryoho 2000;27 Suppl 2:432–5.

    PubMed  Google Scholar 

  97. Amesur NB, Zajko AB, Carr BI. Chemo-embolization for unresectable hepatocellular carcinoma with different sizes of embolization particles. Dig Dis Sci 2008;53:1400–4.

    PubMed  Google Scholar 

  98. Carr B, Selby R, Madariaga J, et al. A controlled, prospective randomized trial comparing intra-arterial cisplatin and doxorubicin with or without Lipiodol for hepatocellular carcinoma. Hepatology 1992;16:60.

    Google Scholar 

  99. Liebman HA, Furie BC, Tong MJ, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984;310:1427–31.

    PubMed  CAS  Google Scholar 

  100. Ebied OM, Federle MP, Carr BI, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 2003;97:1042–50.

    PubMed  Google Scholar 

  101. Katyal S, Oliver JH, Peterson MS, Chang PJ, Baron RL, Carr BI. Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: a retrospective analysis. AJR Am J Roentgenol 2000;175:1665–72.

    PubMed  CAS  Google Scholar 

  102. Malagari K, Chatzimichael K, Alexopoulou E, et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 2008;31:269–80.

    PubMed  Google Scholar 

  103. Poon RT, Tso WK, Pang RW, et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007;5:1100–8.

    PubMed  CAS  Google Scholar 

  104. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46:474–81.

    PubMed  CAS  Google Scholar 

  105. Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999;5:1676–81.

    PubMed  CAS  Google Scholar 

  106. Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002;94:421–7.

    PubMed  CAS  Google Scholar 

  107. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532–8.

    PubMed  CAS  Google Scholar 

  108. Carr BI, Wang Z, Kar S. K vitamins, PTP antagonism, and cell growth arrest. J Cell Physiol 2002;193:263–74.

    PubMed  CAS  Google Scholar 

  109. Nakao A, Virji A, Iwaki Y, Carr B, Iwatsuki S, Starzl E. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma. Hepatogastroenterology 1991;38:450–3.

    PubMed  CAS  Google Scholar 

  110. Habu D, Shiomi S, Tamori A, et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 2004;292:358–61.

    PubMed  CAS  Google Scholar 

  111. Kakizaki S, Sohara N, Sato K, et al. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J Gastroenterol Hepatol 2007;22:518–22.

    PubMed  CAS  Google Scholar 

  112. Mizuta T, Ozaki I, Eguchi Y, et al. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer 2006;106:867–72.

    PubMed  CAS  Google Scholar 

  113. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet 1998;352:17–20.

    Google Scholar 

  114. Farinati F, De Maria N, Fornasiero A, et al. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Dig Dis Sci 1992;37:659–62.

    PubMed  CAS  Google Scholar 

  115. Liu CL, Fan ST, Ng IO, Lo CM, Poon RT, Wong J. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol 2000;95:218–22.

    PubMed  CAS  Google Scholar 

  116. Martinez Cerezo FJ, Tomas A, Donoso L, et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994;20:702–6.

    PubMed  CAS  Google Scholar 

  117. Barbare JC, Bouche O, Bonnetain F, et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 2005;23:4338–46.

    PubMed  CAS  Google Scholar 

  118. Gallo C, De Maio E, Di Maio M, et al. Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma. BMC Cancer 2006;6:196.

    PubMed  Google Scholar 

  119. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. Hepatology 2004;40:1361–9.

    Google Scholar 

  120. Grimaldi C, Bleiberg H, Gay F, et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol 1998;16:411–7.

    PubMed  CAS  Google Scholar 

  121. Falkson G, Lipsitz S, Borden E, Simson I, Haller D. Hepatocellular carcinoma. An ECOG randomized phase II study of beta-interferon and menogaril. Am J Clin Oncol 1995;18:287–92.

    PubMed  CAS  Google Scholar 

  122. Lai CL, Lau JY, Wu PC, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993;17:389–94.

    PubMed  CAS  Google Scholar 

  123. Lai CL, Wu PC, Lok AS, et al. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer 1989;60:928–33.

    PubMed  CAS  Google Scholar 

  124. Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54–8.

    PubMed  CAS  Google Scholar 

  125. Becker G, Allgaier HP, Olschewski M, Zahringer A, Blum HE. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007;45:9–15.

    PubMed  CAS  Google Scholar 

  126. Cebon J, Findlay M, Hargreaves C, et al. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer 2006;95:853–61.

    PubMed  CAS  Google Scholar 

  127. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 2002;49:1245–50.

    PubMed  CAS  Google Scholar 

  128. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol 2007;13:3164–70.

    PubMed  CAS  Google Scholar 

  129. Rabe C, Pilz T, Allgaier HP, et al. [Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide.]. Z Gastroenterol 2002;40:395–400.

    PubMed  CAS  Google Scholar 

  130. Slijkhuis WA, Stadheim L, Hassoun ZM, et al. Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol 2005;39:333–8.

    PubMed  CAS  Google Scholar 

  131. Verset G, Verslype C, Reynaert H, et al. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer 2007;97:582–8.

    PubMed  CAS  Google Scholar 

  132. Chao Y, Chan WK, Wang SS, et al. Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12:277–81.

    PubMed  CAS  Google Scholar 

  133. Villa E, Ferretti I, Grottola A, et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 2001;84:881–5.

    PubMed  CAS  Google Scholar 

  134. Carr BI. Complete suppression of DCP/PIVKA 2 levels by vitamin K1 administration to patients with hepatocellular carcinoma (HCC). Hepatology 1993;18:500.

    Google Scholar 

  135. Carr BI. A phase I/phase II study of high-dose vitamin K in patients with advanced, inoperable hepatocellular carcinoma. Proc AASLD Hepatology 1994;20:727.

    Google Scholar 

  136. Zamibone A, Biasi L, Graffeo M, et al. Phase II study of high-dose vitamin K1 in hepatocellular carcinoma. Proc ASCO 1998;17:307A.

    Google Scholar 

  137. Chuah B, Lim R, Boyer M, et al. Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncol 2007;46:234–8.

    PubMed  CAS  Google Scholar 

  138. Lin AY, Brophy N, Fisher GA, et al. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 2005;103:119–25.

    PubMed  CAS  Google Scholar 

  139. Patt YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 2000;23:319–21.

    PubMed  CAS  Google Scholar 

  140. Patt YZ, Hassan MM, Lozano RD, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 2005;103:749–55.

    PubMed  CAS  Google Scholar 

  141. Pinter M, Wichlas M, Schmid K, et al. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial. Eur J Gastroenterol Hepatol 2008;20:1012–9.

    PubMed  CAS  Google Scholar 

  142. Schwartz JD, Sung M, Schwartz M, et al. Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist 2005;10:718–27.

    PubMed  CAS  Google Scholar 

  143. Yau T, Chan P, Wong H, et al. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. Oncology 2007;72 Suppl 1:67–71.

    PubMed  CAS  Google Scholar 

  144. Zhu AX, Stuart K, Blaszkowsky LS, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007;110:581–9.

    PubMed  CAS  Google Scholar 

  145. Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, Yang CH. Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest New Drugs 2007;25:77–84.

    PubMed  CAS  Google Scholar 

  146. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26:2992–8.

    PubMed  CAS  Google Scholar 

  147. Palmer DH, Midgley RS, Mirza N, et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 2008;3:3.

    Google Scholar 

  148. Borbath I, Lhommel R, Bittich L, et al. 131I-Labelled-iodized oil for palliative treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005;17:905–10.

    PubMed  CAS  Google Scholar 

  149. Brans B, Van Laere K, Gemmel F, et al. Combining iodine-131 Lipiodol therapy with low-dose cisplatin as a radiosensitiser: preliminary results in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2002;29:928–32.

    PubMed  CAS  Google Scholar 

  150. Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999;353:797–801.

    PubMed  CAS  Google Scholar 

  151. Leung WT, Lau WY, Ho S, et al. Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma. J Nucl Med 1994;35:1313–8.

    PubMed  CAS  Google Scholar 

  152. Order S, Pajak T, Leibel S, et al. A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: an RTOG study. Int J Radiat Oncol Biol Phys 1991;20:953–63.

    PubMed  CAS  Google Scholar 

  153. Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004;10:S107–10.

    PubMed  Google Scholar 

  154. Carr BI, Amesur N, Zajko A, et al. Safety and efficacy of hepatic artery 90Y microspheres in unresectable hepatocellular carcinoma (HCC). Proc ASCO 2003;22:1046.

    Google Scholar 

  155. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000;41:1673–81.

    PubMed  CAS  Google Scholar 

  156. Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998;40:583–92.

    PubMed  CAS  Google Scholar 

  157. Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 2002;13:S223–9.

    PubMed  Google Scholar 

  158. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47:71–81.

    PubMed  Google Scholar 

  159. Couto OF, Dvorchik I, Carr BI. Causes of death in patients with unresectable hepatocellular carcinoma. Dig Dis Sci 2007;52:3285–9.

    PubMed  CAS  Google Scholar 

  160. Thomas MB. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). In: ASCO Annual Meeting; 2007; 2007.

    Google Scholar 

  161. Carr BI. Chemotherapy in Diagnosis and treatment of HCC. Livraghi T, Mukuuchi M and Buscarini L eds. Greenwich Medical 1997; pp. 367–391

    Google Scholar 

  162. Llovet, JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. Nwe Engl J Med 2008; 259: 378–390.

    Google Scholar 

  163. Thomas MB, Morris JS, Chadha R et al. Phase II trial of Bevacizumab and Erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009. Jan 12 epub.

    Google Scholar 

  164. Carr BI. Gemcitabine hepatic arterial chemo-embolization in the treatment of hepatocellular carcinoma. Proc. ASCO 2006;24:4141

    Google Scholar 

  165. Collins J. Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984; 2: 498–504.

    PubMed  CAS  Google Scholar 

  166. Carr BI, Kondragunta V, Olek M, Geller D, Branch R. Prospective evaluation of 3 treatments in 932 patients with unresectable hepatocellular carcinoma (HCC) in a single institution. Proc. AASLD, Hepatology 2006;44(4):885.

    Google Scholar 

  167. Carr BI, Buch SC, Kondragunta V, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study. J Gastroenterol Hepatol 2008;23(8 Pt 1):1259–66.

    Google Scholar 

  168. Gonsalves CF, Brown DB, Carr BI. Regional radioactive treatments for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2008;2(4):453–6.

    Google Scholar 

  169. Nalesnik MA, Federle M, Buck D, Fontes P, Carr BI. Hepatobiliary effects of 90yttrium microsphere therapy for unresectable hepatocellular carcinoma. Hum Pathol 2009 Jan;40(1):125–34.

    Google Scholar 

  170. Carr BI, Amesur NB, Dasyam A. A randomized, controlled study of TACE vs. 90Yttrium microspheres in unresectable HCC: interim results. Proc ASCO 2008;26: 15609.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Liver Tumor Program, Thomas Jefferson University, Philadelphia, PA, USA

    Brian I. Carr MD, FRCP, PhD

  2. Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA

    Srikanth Nagalla MD, MS

Authors
  1. Brian I. Carr MD, FRCP, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Srikanth Nagalla MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Kimmel Cancer Center, Thomas Jefferson University, S. 10th Street 233, Philadelphia, 19107, Pennsylvania, USA

    Brian I. Carr

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Carr, B.I., Nagalla, S. (2009). Medical Therapy of HCC. In: Carr, B. (eds) Hepatocellular Carcinoma. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-60327-376-3_20

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-376-3_20

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-373-2

  • Online ISBN: 978-1-60327-376-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation